1 / 15

Aarkstore - Depression - Pipeline Review, H2 2014

“Depression - Pipeline Review, H2 2014”report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications.

addyparker2350
Télécharger la présentation

Aarkstore - Depression - Pipeline Review, H2 2014

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Category : Healthcare  Depression - Pipeline Review, H2 2014 Browse Complete Report - http://www.aarkstore.com/healthcare/63079/depression-pipeline-review

  2. Depression - Pipeline Review, H2 2014

  3. Summary Global Markets Direct’s, ‘Depression - Pipeline Review, H2 2014’, provides an overview of the Depression’s therapeutic pipeline.This report provides comprehensive information on the therapeutic development for Depression, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Depression and special features on late-stage and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

  4. Summary Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

  5. Scope - The report provides a snapshot of the global therapeutic landscape of Depression- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Depression and enlists all their major and minor projects- The report summarizes all the dormant and discontinued pipeline projects - A review of the Depression products under development by companies and universities/research institutes based on information derived from company and industry-specific sources- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages- A detailed assessment of monotherapy and combination therapy pipeline projects- Coverage of the Depression pipeline on the basis of target, MoA, route of administration and molecule type- Latest news and deals relating related to pipeline products

  6. Reasons to buy Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage- Develop strategic initiatives by understanding the focus areas of leading companies- Identify and understand important and diverse types of therapeutics under development for Depression- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline- Devise corrective measures for pipeline projects by understanding Depression pipeline depth and focus of Indication therapeutics- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

  7. Table of Content List of Tables 7List of Figures 9Introduction 10Global Markets Direct Report Coverage 10Depression Overview 11Therapeutics Development 12Pipeline Products for Depression - Overview 12Pipeline Products for Depression - Comparative Analysis 13Depression - Therapeutics under Development by Companies 14Depression - Therapeutics under Investigation by Universities/Institutes 20Depression - Pipeline Products Glance 22Late Stage Products 22Clinical Stage Products 23Early Stage Products 24Unknown Stage Products 25Depression - Products under Development by Companies 26

  8. Table of Content Depression - Products under Investigation by Universities/Institutes 32Depression - Companies Involved in Therapeutics Development 34AB Science 34Acetylon Pharmaceuticals, Inc. 35Ache Laboratorios Farmaceuticos S/A 36Adamas Pharmaceuticals, Inc. 37Adamed Sp. z o.o. 38Addex Therapeutics Ltd 39Anavex Life Sciences Corp. 40Angelini Group 41Angita B.V. 42ArisGen SA 43Azevan Pharmaceuticals, Inc. 44

  9. List Of Tables Number of Products under Development for Depression, H2 2014 19Number of Products under Development for Depression - Comparative Analysis, H2 2014 20Number of Products under Development by Companies, H2 2014 22Number of Products under Development by Companies, H2 2014 (Contd..1) 23Number of Products under Development by Companies, H2 2014 (Contd..2) 24Number of Products under Development by Companies, H2 2014 (Contd..3) 25Number of Products under Development by Companies, H2 2014 (Contd..4) 26Number of Products under Investigation by Universities/Institutes, H2 2014 28Comparative Analysis by Late Stage Development, H2 2014 29Comparative Analysis by Clinical Stage Development, H2 2014 30Comparative Analysis by Early Stage Development, H2 2014 31

  10. List Of Tables Comparative Analysis by Unknown Stage Development, H2 2014 32Products under Development by Companies, H2 2014 33Products under Development by Companies, H2 2014 (Contd..1) 34Products under Development by Companies, H2 2014 (Contd..2) 35Products under Development by Companies, H2 2014 (Contd..3) 36Products under Development by Companies, H2 2014 (Contd..4) 37Products under Development by Companies, H2 2014 (Contd..5) 38Products under Investigation by Universities/Institutes, H2 2014 39Products under Investigation by Universities/Institutes, H2 2014 (Contd..1) 40Depression - Pipeline by AB Science, H2 2014 41Depression - Pipeline by Acetylon Pharmaceuticals, Inc., H2 2014 42Depression - Pipeline by Ache Laboratorios Farmaceuticos S/A, H2 2014 43Depression - Pipeline by Adamas Pharmaceuticals, Inc., H2 2014 44Depression - Pipeline by Adamed Sp. z o.o., H2 2014 45

  11. List of Figures Number of Products under Development for Depression, H2 2014 19 Number of Products under Development for Depression - Comparative Analysis, H2 2014 20 Number of Products under Development by Companies, H2 2014 21 Number of Products under Investigation by Universities/Institutes, H2 2014 27 Comparative Analysis by Clinical Stage Development, H2 2014 30 Comparative Analysis by Early Stage Products, H2 2014 31 Assessment by Monotherapy Products, H2 2014 92 Number of Products by Top 10 Targets, H2 2014 93 Number of Products by Stage and Top 10 Targets, H2 2014 93 Number of Products by Top 10 Mechanism of Actions, H2 2014 97 Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 97 Number of Products by Top 10 Routes of Administration, H2 2014 100

  12. Related Reports • Epilepsy Market in the US 2015-2019 • Global Ankylosing Spondylitis Market 2015-2019 • Sickle-cell Anemia Therapeutics Market in the US 2015-2019 • Onchocerciasis (River Blindness) Global Clinical Trials Review, H2, 2014

  13. Related Reports • Mycoses Global Clinical Trials Review, H2, 2014 • Nosocomial Infections Global Clinical Trials Review, H2, 2014 • Orthomyxoviridae Infections Global Clinical Trials Review, H2, 2014 • Pediculosis (Head Lice Infestation) Global Clinical Trials Review, H2, 2014 • Healthcare Market Research Reports

  14. Depression - Pipeline Review, H2 2014 Published: Oct 2014 | 225 Pages Depression - Pipeline Review, H2 2014 report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Price

  15. Contact Us Office Office No. - 809, 8th Floor,B-Wing, Mahaavir Icon, Plot No.- 89 & 90, Sector-15,CBD-Belapur, Navi Mumbai – 400614, Maharashtra, India. Telefax No: +91 22 4127 6660 24/7 Online Support: +91 9987295242 General Inquiries : +91 - 22 2756 4953 You Can Visit http://www.aarkstore.com OR Mail us at contact@aarkstore.com Blog : http://www.aarkstore.com/blog/ Conference : http://conference.aarkstore.com/ News : http://www.aarkstore.com/news

More Related